Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
2020; Lippincott Williams & Wilkins; Volume: 38; Issue: 28 Linguagem: Inglês
10.1200/jco.20.00522
ISSN1527-7755
AutoresFilip Janků, Albiruni R. Abdul Razak, Ping Chi, Michael C. Heinrich, Margaret von Mehren, Robin L. Jones, Kristen N. Ganjoo, Jonathan C. Trent, Hans Gelderblom, Neeta Somaiah, Simin Hu, Oliver Rosen, Ying Su, Rodrigo Ruiz‐Soto, Michael S. Gordon, Suzanne George,
Tópico(s)Neurofibromatosis and Schwannoma Cases
ResumoIn advanced gastrointestinal stromal tumor (GIST), there is an unmet need for therapies that target both primary and secondary mutations of pathogenic KIT/PDGFRA oncoproteins. Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of
Referência(s)